| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 2 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma | New England Journal of Medicine | 2007 | 4,569 |
| 3 | Exosomes: composition, biogenesis and function | Nature Reviews Immunology | 2002 | 4,401 |
| 4 | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Nature | 2005 | 3,221 |
| 5 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
| 6 | The Pathophysiology of Mitochondrial Cell Death | Science | 2004 | 2,960 |
| 7 | Mitochondrial control of cell death | Nature Medicine | 2000 | 2,937 |
| 8 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Lancet, The | 2008 | 2,848 |
| 9 | Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients | Radiotherapy and Oncology | 2009 | 2,607 |
| 10 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Science | 2015 | 2,539 |
| 11 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | New England Journal of Medicine | 2017 | 2,256 |
| 12 | Innate or Adaptive Immunity? The Example of Natural Killer Cells | Science | 2011 | 2,234 |
| 13 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Lancet, The | 2007 | 2,140 |
| 14 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Nature | 2014 | 2,109 |
| 15 | Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes | Nature Medicine | 1998 | 1,908 |
| 16 | AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 1,802 |
| 17 | Renal cell carcinoma | Nature Reviews Disease Primers | 2017 | 1,727 |
| 18 | Nasopharyngeal carcinoma | Lancet, The | 2019 | 1,667 |
| 19 | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial | Lancet, The | 2013 | 1,664 |
| 20 | Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy | Clinical Cancer Research | 2005 | 1,618 |
| 21 | Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors | Nature Medicine | 2009 | 1,614 |
| 22 | Mutation inTET2in Myeloid Cancers | New England Journal of Medicine | 2009 | 1,614 |
| 23 | The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide | Science | 2013 | 1,580 |
| 24 | Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission | New England Journal of Medicine | 1999 | 1,562 |
| 25 | Inhibition of Macroautophagy Triggers Apoptosis | Molecular and Cellular Biology | 2005 | 1,533 |
| 26 | Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) | Head and Neck | 2005 | 1,412 |
| 27 | Immunological aspects of cancer chemotherapy | Nature Reviews Immunology | 2008 | 1,374 |
| 28 | Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming | Nature Medicine | 2001 | 1,362 |
| 29 | Organelle-specific initiation of cell death pathways | Nature Cell Biology | 2001 | 1,320 |
| 30 | Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV | Radiotherapy and Oncology | 2005 | 1,315 |
| 31 | Autophagic cell death: the story of a misnomer | Nature Reviews Molecular Cell Biology | 2008 | 1,291 |
| 32 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2014 | 1,280 |
| 33 | Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death | Journal of Experimental Medicine | 2005 | 1,224 |
| 34 | Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death | Nature | 2001 | 1,212 |
| 35 | Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte | Blood | 2010 | 1,193 |
| 36 | A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 | Nature | 2008 | 1,169 |
| 37 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Lancet, The | 2012 | 1,165 |
| 38 | Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice | Science | 2011 | 1,159 |
| 39 | Lysosomes and autophagy in cell death control | Nature Reviews Cancer | 2005 | 1,135 |
| 40 | Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Cancer Immunology, Immunotherapy | 2007 | 1,104 |
| 41 | Cell death by mitotic catastrophe: a molecular definition | Oncogene | 2004 | 1,074 |
| 42 | Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value | PLoS Medicine | 2013 | 1,064 |
| 43 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 1,039 |
| 44 | Mechanisms of cytochrome c release from mitochondria | Cell Death and Differentiation | 2006 | 1,028 |
| 45 | Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper | Journal of Extracellular Vesicles | 2015 | 1,020 |
| 46 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial | Journal of Clinical Oncology | 2009 | 1,007 |
| 47 | Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults | JAMA Internal Medicine | 2016 | 1,000 |
| 48 | Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial | Lancet Oncology, The | 2013 | 998 |
| 49 | Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial | Journal of Translational Medicine | 2005 | 993 |
| 50 | Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study | Lancet, The | 2003 | 988 |
